<DOC>
	<DOCNO>NCT00338936</DOCNO>
	<brief_summary>This study design provide long-term safety efficacy data combination dose VAH ( VAL/ HCTZ ) 40/6.25mg 80/12.5mg essential hypertensive patient . The 350 patient ( approximately ) successfully finish core trial CVAH631B1303 sign consent extension enrol study .</brief_summary>
	<brief_title>Long Term Study VAH631 Patients With Essential Hypertension ( Extension From B1303 Study )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients successfully complete core study ( Protocol 1303 ) Outpatients Presence crucial protocol violation Protocol 1303 Patients experienced adverse event consider serious drug relate Protocol 1303 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Hydrochlorothiazide</keyword>
</DOC>